Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q3 EPS of $2.05, $0.21 better than the analyst estimate of $1.84. Revenue for the quarter came in at $127.34 million versus the consensus estimate of $126.77 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.